A Phase 1 interventional study of ZSP1601 25 mg and Placebo 25mg in Nonalcoholic Steatohepatitis (NASH), sponsored by Guangdong Zhongsheng Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-13.
Sponsored by Guangdong Zhongsheng Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 54 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.
Among the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 52nd largest by enrollment of the 89 interventional ones that give a count, is one of 8 that started in 2018, is one of 18 in phase 1, and was the 27th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →42 of the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Liu Yan · Sites in China
Ages 18–65
The Affiliated Hospital of Hangzhou Normal University · Sites in China
Ages 65–100 · Healthy volunteers
Hudson Biotech · Sites in China
Ages 18–75
Eli Lilly and Company · Sites in China, United States, Argentina and 31 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 22 · Phase 3 7 · Phase 4 11
First in 2004; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 94 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 112 across the 89 interventional studies, 880 across the 53 observational. Of the 61 that completed or were terminated, 6 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 142 have an industry lead sponsor. The 10 most frequent:
Guangdong Zhongsheng Pharmaceutical Co., Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. has 4 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Non-alcoholic Fatty Liver Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06449833Zhujiang HospitalEffect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD | 2026-11 |
| NCT02863757Humanity and Health Research CentreFollow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease | 2026-12 |
| NCT06569524Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) | 2026-12 |
| NCT07099118Sunshine Lake Pharma Co., Ltd.A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects | 2026-12-30 |
| NCT06717828Fujian Provincial HospitalThe Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single- and multiple-oral doses of ZSP1601 on fasted condition, and characterize PK of ZSP1601 on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed condition) in a 2-period, 2-sequence manner. The study will be conducted in 3 parts (Ascending single dose, multiple dose and food effect). Participants will receive either ZSP1601 or placebo .
The study is a randomized, double-blind phase 1 trial including 3 parts: single ascending dose(SAD) part,multiple ascending dose(MAD) part and postprandial pharmacokinetics part.The primary aims of the study as below:
Evaluating the safety and tolerance of single and multiple dose of ZSP1601 in healthy volunteers.
Evaluating the fasting and postprandial pharmacokinetic parameters of ZSP1601 in healthy volunteers.
Eligible participants will be admitted to the trial center on Day -1. Subjects will be randomly assigned to either experimental groups or placebo groups, according to a randomisation schedule in a (4:1) ratio (8 in per experimental group). Subjects in SAD will receive 25、50、100、175、275、350 mg once daily respectively.Each dose will be administrated after assurance of safety for the former dose. Subjects in MAD will receive 50 or 100 mg once daily for 14days respectively.The treatment in food effect consists of 2 periods,and subjects will receive 100mg on fasting and postprandial states respectively. There will be a 7-day wash out period between treatment periods.To monitor AEs,record abnormalities (12-lead ECG,Vital signs,Physical examination,Clinical Laboratory),and detect the pharmacokinetics of ZSP1601.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects are required to meet the following criteria in order to be included in the trial:
Exclusion Criteria:
Eligible subjects must not meet any of the following exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZSP1601 25 mg /Placebo
Drug: ZSP1601 25 mg · Drug: Placebo 25mg
ZSP1601 50 mg/Placebo Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1.
Drug: ZSP1601 50 mg · Drug: Placebo 50 mg
ZSP1601 100 mg/Placebo Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2.
Drug: ZSP1601 100 mg · Drug: Placebo 100 mg
ZSP1601 175 mg/Placebo Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3.
Drug: ZSP1601 175 mg · Drug: Placebo 175 mg
ZSP1601 275 mg/Placebo Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4.
Drug: ZSP1601 275 mg · Drug: Placebo 275 mg
ZSP1601 350 mg/Placebo Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5.
Drug: ZSP1601 350 mg · Drug: Placebo 350mg
Period 1 (Day1 to Day4): Group A and Group B receive ZSP1601 100 mg/Placebo under the fasting or fed condition ,respectively on Day1. Period 2 (Day 8 to Day11): Group A and Group B receive ZSP1601 100 mg/Placebo under the fed or fasting condition ,respectively on Day8.
Drug: ZSP1601 100 mg · Drug: Placebo 100mg
50 mg ZSP1601 will be administrated while fasted or fed according to the results of Cohort FE ZSP1601 50 mg/Placebo for 14 Days.
Drug: ZSP1601 50 mg · Drug: Placebo 50 mg
Enrollment into Cohort 8 will begin upon assurance of safety for Cohort 7. ZSP1601 100 mg/Placebo for 14 Days.
Drug: ZSP1601 100 mg · Drug: Placebo 100 mg
ZSP1601 tablet administered orally once daily under fasted condition
Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
ZSP1601 tablet administered orally once daily under fasted condition
Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
ZSP1601 tablets administered orally once daily in the fasting state
Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
ZSP1601 tablets administerekd orally once daily under fasted condition
Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
ZSP1601 tablets administered orally once daily in the fasting state
Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
ZSP1601 tablets administered orally once daily under fasted condition
Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
ZSP1601 tablets administered orally once daily under fasted or fed condition
Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE) following oral doses(single,multiple and food effect)of ZSP1601 and placebo.
Time frame: SAD Group: Up to 4 days, MAD: Up to 17days, FE group: Up to 11 days after first dose
Concomitant Medication
Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
Clinical Laboratory Abnormalities(Blood routine test, serum biochemical test, conventional coagulation examinations, urine examination ) post dose of ZSP1601 and placebo.
Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
12-lead ECG Abnormalities following oral dosing of ZSP1601 and placebo.
Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
Vital signs Abnormalities following oral dosing of ZSP1601 and placebo.
Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
Physical examination Abnormalities following oral dossing of ZSP1601 and placebo.
Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
Cardiac color ultrasound(UCG) Abnormalities following multiple oral doses of ZSP1601 and placebo.
Time frame: Screening, Day17
AUClast(AUC0-t)of ZSP1601
AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.
Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively
AUCinf(AUC0-∞)of ZSP1601
AUCinf is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).
Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively
Cmax of ZSP1601
Cmax is defined as the maximum observed concentration of drug in plasma.
Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively
Tmax of ZSP1601
Tmax is defined as the time to maximum concentration.
Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively
t1/2z of ZSP1601
t1/2z is defined as the time to decline half of the drug concentration in plasma.
Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively
Single-dose PK Parameter: Ae of ZSP1601
Ae is defined as the amount of unchanged drug excreted in urine or faeces after administration.
Time frame: Up to Day 2 post-dose
Single-dose PK Parameter: Fe0-t of ZSP1601
Fe0-t is defined as the cumulative excretion rate of the drug in urine and feces.
Time frame: Up to Day 2 post-dose
CL/F of ZSP1601
CL/F is defined as the ratio of total clearance(Cl) to bioavailability(F).
Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively
λz of ZSP1601
λz is defined as the ratio between the elimination of compound per unit time and the total amount of compound.
Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively
CLr of ZSP1601
CLr is defined as how many milliliters of plasma in which some substance can be completely eliminated in the unit time (per minute) of two kidneys
Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively
Multiple-dose plasma PK parameter: Rac of ZSP1601 at steady state
Rac (Accumulation Index) is defined as the ratio between AUC0-XX in Day XX and AUC0-XX in Day1
Time frame: Up to 16days
Multiple-dose plasma PK parameter: DF of ZSP1601 at steady state
DF is defined as the percentage of fluctuation in steady state is 100 \* (Cmax, ss - Cmin, ss)/Cavg, ss.
Time frame: Up to 16 days
Multiple-dose plasma PK parameter: Cmin of ZSP1601 at steady state
Cmin is defined as the minimum observed concentration of drug in plasma at steady state.
Time frame: Up to 16days
Ran from Jan 2018 to primary completion in Dec 2018, 11 months.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 11 months is close to that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZSP1601
Non-alcoholic Fatty Liver Disease →
Guangdong Zhongsheng Pharmaceutical Co., Ltd. →